CENPN and breast neoplasm: In TIDE, immunotherapy was more effective in treating breast tumors with high CENPN expression, raising the possibility that it could be used as a biomarker for predicting treatment effectiveness of immune checkpoint inhibitors and serve as a potential novel immunotherapy target.